ClinicalTrials.gg
TerminatedNCT03605212FLORETUpdated Jun 3, 2021Results posted

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

A Phase 1/2 interventional study of Febuxostat in Tumor Lysis Syndrome, sponsored by Menarini Group. Terminated at 17 sites in 4 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Menarini Group · Phase 1/2, Interventional, and Prevention

Why this study was terminated
The study was stopped as per EMA waiver granted on 20July2018.

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6\<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect in terms of serum uric acid levels.

Read the detailed description

In the FLORET study it is planned to enroll 3 groups of patients in order to receive oral administration (film-coated tablets) of two different dose levels of febuxostat: children (from 6 to less than 12 years of age) will receive two different dose levels respectively; adolescents (from 12 to less than 18 years of age) will receive 80 and 120 mg/day respectively and adults (equal or major than 18 years of age) will receive 120 mg/day. The two dose levels for children and adolescents groups were to be sequentially administered, whereas the groups that will receive the first dose levels will simultaneously start the treatment at the study beginning. The individual treatment duration will be of 7 to 9 days, according to chemotherapy duration, as per Investigator's judgement.

02

Conditions studied

  • Tumor Lysis Syndrome

Keywords

  • TLS
  • FLO-02
  • Hematological Malignancies
03

In context

Tumor Lysis Syndrome

20 studies on the registry are indexed under Tumor Lysis Syndrome; 1 is open to participants now.

This study's enrollment of 30 is below the median of 55 across 13 interventional studies indexed under Tumor Lysis Syndrome.

Browse Tumor Lysis Syndrome studies →

Lead sponsor

Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

male and female children of 6 to less than 12 years of age, adolescents of 12 to less than 18 years of age and adults from 18 years:

  • scheduled for first cytotoxic chemotherapy cycle because of hematologic
  • and at intermediate or high risk of TLS
  • and with no access to rasburicase

Exclusion criteria

Exclusion Criteria:

  • patients with as per febuxostat summary of product characteristics
  • patients with severe renal insufficiency
  • patients with severe hepatic insufficiency
  • patients with diagnosis of Laboratory TLS (LTLS) or Clinical TLS (CTLS)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days

    Drug: Febuxostat

  • Experimental
    Cohort 2

    Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days

    Drug: Febuxostat

  • Experimental
    Cohort 3

    Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)

    Drug: Febuxostat

  • Experimental
    Cohort 4

    Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)

    Drug: Febuxostat

  • Active comparator
    Adults

    Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)

    Drug: Febuxostat

Interventions

  • Intervention is orally administered to patients in this arm.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)

    Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

    Time frame: 7 days

  2. PK Parameter: Apparent Volume of Distribution (Vd/F)

    Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

    Time frame: 7 days

  3. PK Parameter: Absorption Rate Constant (Ka)

    Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

    Time frame: 7 days

  4. PK Parameter: Area Under Curve (AUC)

    AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

    Time frame: 7 days

  5. PK Parameter: Maximum Plasma Concentration (Cmax)

    Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

    Time frame: 7 days

  6. PK Parameter: Tmax

    Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

    Time frame: 7 days

Secondary outcomes

  1. Pharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)

    Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)

    Time frame: 8 days

  2. Assessment of Laboratory Tumor Lysis Syndrome (LTLS)

    Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.

    Time frame: 7 days

  3. Assessment of Clinical Tumor Lysis Syndrome (CTLS)

    Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.

    Time frame: 7 days

  4. Assessment of Treatment Emergent Signs and Symptoms (TESS)

    Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.

    Time frame: Estimated maximum time frame: 27 days

  5. Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)

    Number of participants affected by TESS from Screening Visit to End of Study Visit.

    Time frame: Estimated maximum time frame: 27 days

  6. Performance Status (PS) Evaluation

    Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).

    Time frame: Estimated maximum time frame: 27 days

07

Results

Posted Jun 3, 2021
Limitations and caveats
Data for all outcome measures were not collected due to the paucity of data in the minor patient population and in agreement with EMA with the exceptions of the secondary outcome Assessment of Treatment Emergent Signs and Symptoms (TESS).

Participant flow

The first patient was screened and enrolled on 27 Feb 2017. The last patient completed the study on 16 Jul 2018. The study was conducted at 17 sites in 4 European countries.

Baseline Period
Participant flow — Baseline Period
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Adults
Started303024
Completed303024
Not completed00000
Treatment Period
Participant flow — Treatment Period
MilestoneCohort 1Cohort 2Cohort 3Cohort 4Adults
Started303024
Completed203023
Not completed10001
Withdrew: Adverse event10000
Withdrew: Physician decision00001

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: Apparent Clearance (CL/F)

Apparent clearance of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

Time frame:
7 days

No measurements were reported for this outcome.

PrimaryPK Parameter: Apparent Volume of Distribution (Vd/F)

Apparent volume of distribution of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

Time frame:
7 days

No measurements were reported for this outcome.

PrimaryPK Parameter: Absorption Rate Constant (Ka)

Absorption rate constant of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

Time frame:
7 days

No measurements were reported for this outcome.

PrimaryPK Parameter: Area Under Curve (AUC)

AUC of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

Time frame:
7 days

No measurements were reported for this outcome.

PrimaryPK Parameter: Maximum Plasma Concentration (Cmax)

Maximum plasma concentration of febuxostat from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

Time frame:
7 days

No measurements were reported for this outcome.

PrimaryPK Parameter: Tmax

Time to Cmax from Visit 2 (Day 2) to Evaluation Visit (Visit 8, Day 8)

Time frame:
7 days

No measurements were reported for this outcome.

SecondaryPharmacodynamic (PD) Parameter: Area Under the Curve of Serum Uric Acid (sUA)

Area under the curve of sUA from baseline (Visit 1, Day 1) to the Evaluation Visit (Visit 8, Day 8) (AUC sUA 1-8)

Time frame:
8 days

No measurements were reported for this outcome.

SecondaryAssessment of Laboratory Tumor Lysis Syndrome (LTLS)

Assessment of LTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). LTLS is diagnosed if levels of 2 or more values of uric acid, potassium, phosphate or calcium are more than or less than normal at presentation or if they change by at least 25% from baseline.

Time frame:
7 days

No measurements were reported for this outcome.

SecondaryAssessment of Clinical Tumor Lysis Syndrome (CTLS)

Assessment of CTLS at Visit 1 (Day 1) and from Start of Chemotherapy (Visit 3, Day 3) to the Evaluation Visit (Visit 8, Day 8). CTLS is present when LTLS is accompanied by at least one of the following significant clinical complications: increased creatinine level ≥ 1.5 upper limit of normal, cardiac arrhythmia/sudden death or seizure.

Time frame:
7 days

No measurements were reported for this outcome.

SecondaryAssessment of Treatment Emergent Signs and Symptoms (TESS)

Assessment of incidence, severity (through Mild/Moderate/Severe scale), seriousness and treatment-causality of TESS from Screening Visit to End of Study Visit. Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. An adverse event was considered as TESS if it occured for the first time or if it worsened in terms of seriousness or severity after first study drug intake.

Time frame:
Estimated maximum time frame: 27 days
Reported as:
Number · Events
Assessment of Treatment Emergent Signs and Symptoms (TESS)
EventsCohort 1Cohort 2Cohort 3Cohort 4Adults
TESS50—21—70
TESS grade >/=311—2—20
Serious TESS1—0—7
Related TESS4—0—0
Related TESS grade >/=32—0—0
Related TESS/Drug Withdrawn2—0—0
SecondaryAssessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)

Number of participants affected by TESS from Screening Visit to End of Study Visit.

Time frame:
Estimated maximum time frame: 27 days
Reported as:
Number · participants
Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)
participantsCohort 1Cohort 2Cohort 3Cohort 4Adults
Assessment of Participants Affected by Treatment Emergent Signs and Symptoms (TESS)3—3—20
SecondaryPerformance Status (PS) Evaluation

Quality of life was to be assessed by PS evaluation from Screening Visit to End of Study Visit. The Karnofsky Performance Status (KPS) scale was to be used for patients aged 16 years and older; the Lansky Play Performance Status (LPS) scale was to be used for patients aged less than 16 years. Both scales range from scores of 0 to 100 points at intervals of 10 where 0 points represent the worst outcome (KPS: 0 = death; LPS: 0 = unresponsive) and 100 points the best (KPS: 100 = normal, no complaints, no evidence of disease; LPS: 100 = fully active).

Time frame:
Estimated maximum time frame: 27 days

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected over the entire duration of a patient's study participation, i.e. approximately 3 weeks. In addition, if after the end of the study the Investigator became aware of any AEs or follow-up in AEs already recorded, this information could be recorded in the eCRF until it was available.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 11/3 (33.3%)1/3 (33.3%)3/3 (100%)
Cohort 2———
Cohort 30/3 (0%)0/3 (0%)3/3 (100%)
Cohort 4———
Adults0/24 (0%)5/24 (20.8%)20/24 (83.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 3Cohort 4Adults
Septioc shockInfections and infestations1/3—0/3—1/24
Enterobacter test positivInvestigations0/3—0/3—1/24
Febrile neutropeniaBlood and lymphatic system disorders0/3—0/3—1/24
Mucosal inflammationGeneral disorders0/3—0/3—1/24
Abdominal painGastrointestinal disorders0/3—0/3—1/24
ProctitisGastrointestinal disorders0/3—0/3—1/24
Staphylococcal infectionInfections and infestations0/3—0/3—1/24
Most frequent other events
Showing 10 of 71
Most frequent other events
EventCohort 1Cohort 2Cohort 3Cohort 4Adults
ConstipationGastrointestinal disorders1/3—3/3—4/24
AnaemiaBlood and lymphatic system disorders2/3—0/3—4/24
EpistaxisRespiratory, thoracic and mediastinal disorders2/3—0/3—1/24
Abdominal painGastrointestinal disorders2/3—0/3—4/24
VomitingGastrointestinal disorders2/3—0/3—2/24
HyperglycaemiaMetabolism and nutrition disorders1/3—2/3—1/24
Hot flushVascular disorders0/3—1/3—0/24
AstheniaGeneral disorders1/3—1/3—0/24
InflammationGeneral disorders1/3—0/3—0/24
Oedema peripheralGeneral disorders1/3—0/3—0/24

Baseline characteristics

DAY 1 before first febuxostat dosing.

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
<=18 years303006
Between 18 and 65 years00001414
>=65 years00001010
Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
Mean7.33 ± 1.528—14.00 ± 1.000—60.21 ± 15.37650.30 ± 24.419
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
Female10201114
Male20101316
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
Hispanic or Latino001001
Not Hispanic or Latino30202429
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White30202328
More than one race000000
Unknown or Not Reported001012
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
Hungary0—0—88
Italy3—3—511
Bulgaria0—0—00
Spain0—0—1111
Weight
Weight(kg)Cohort 1Cohort 2Cohort 3Cohort 4AdultsTotal
Mean26.13 ± 2.043—60.47 ± 19.747—75.60 ± 15.46968.92 ± 21.369
08

Study locations

17 sites
  • University Hospital Tsaritsa Yoanna
    Sofia, 1527, Bulgaria
  • Semmelweis Egyetem (paediatric)
    Budapest, 1083, Hungary
  • Semmelweis Egyetem
    Budapest, 1085, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, 4032, Hungary
  • SOC Oncologia Medica A - Centro di Riferimento Oncologico
    Aviano, Pordenone 33081, Italy
  • Policlinico S. Orsola Malpighi
    Bologna, 40138, Italy
  • A.O.U.C. Azienda Ospedaliero - Universitaria Careggi
    Firenze, 50134, Italy
  • Azienda Ospedaliero Universitaria Meyer
    Firenze, 50139, Italy
  • Istituto G Gaslini Ospedale Pediatrico IRCCS
    Genova, 16147, Italy
  • Azienda Ospedaliero-Universitaria Pisana
    Pisa, 56126, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Rome, 00165, Italy
  • Ospedale Infantile Regina Margherita
    Torino, 10126, Italy
  • Azienda Ospedaliera Universitaria Integrata di Verona
    Verona, 37126, Italy
  • Hospital de San Pedro de Alcantara
    Caceres, 10002, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitari i Politècnic La Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Jul 2018, 16 months.

Results were first posted in Jun 2021, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2018
First posted
Jul 30, 2018
StartActual
Feb 27, 2017
Primary completionActual
Jul 25, 2018
CompletionActual
Jul 25, 2018
Results first posted
Jun 3, 2021
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03605212
Lead sponsor
Menarini Group
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Feb 27, 2017
Primary completion
Jul 25, 2018
Completion
Jul 25, 2018
Results posted
Jun 3, 2021
Last update
Jun 3, 2021

Study contacts

Franco Locatelli, Prof, MD
study chair · IRCCS Ospedale Pediatrico Bambino Gesù, Piazza Sant'Onofrio, 4, 00165 Rome, IT

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion